Wells Fargo
ANEB

Wells Fargo’s Anebulo Pharmaceuticals ANEB Stock Holding History

Wells Fargo’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-62
Closed -$178 – 6891
2024
Q1 		$178 Buy
62
+1
+2% +$3 ﹤0.01% 6518
2023
Q4 		$148 Buy
61
+3
+5% +$7 ﹤0.01% 6674
2023
Q3 		$177 Buy
58
+1
+2% +$3 ﹤0.01% 6618
2023
Q2 		$134 Buy
57
+2
+4% +$5 ﹤0.01% 6808
2023
Q1 		$160 Buy
55
+1
+2% +$3 ﹤0.01% 6832
2022
Q4 		$131 Buy
54
+17
+46% +$45 ﹤0.01% 6733
2022
Q3 		$0 Buy
37
+17
+85% +$60 ﹤0.01% 6615
2022
Q2 		$0 Buy
20
+1
+5% +$4 ﹤0.01% 6755
2022
Q1 		$0 Hold
19
– – ﹤0.01% 7002
2021
Q4 		$0 Hold
19
– – ﹤0.01% 7183
2021
Q3 		$0 Hold
19
– – ﹤0.01% 6934
2021
Q2 		$0 Buy
+19
New +$141 ﹤0.01% 6871

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo's ANEB Position: Q2 2024 in Review

Wells Fargo sold out of Anebulo Pharmaceuticals (ANEB) in Q2 2024, closing a stake of 62 shares — an estimated $178 sold.

Wells Fargo first reported a position in ANEB in Q2 2021 and held it in 12 quarters. The position peaked at $178 in Q1 2024. 13 funds tracked by Wall St. Rank hold ANEB as of Q2 2024.

  • Wells Fargo reported no remaining Anebulo Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 62 Anebulo Pharmaceuticals shares in Q2 2024, an estimated $178.
  • Wells Fargo first reported a position in Anebulo Pharmaceuticals in Q2 2021 and held it in 12 quarters.
  • Wells Fargo's Anebulo Pharmaceuticals position peaked at $178 in Q1 2024.
  • 13 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.